Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells

Vaccine

Volumn 27, Issue 46, 2009, Pages 6424-6431

  Hinkula, Jorma ^a,b,c   Walther Jallow, Lilian ^d   Laurén, Anna ^e   Mäkitalo, Barbro ^d   Öberg, Monica ^e   Wahren, Britta ^a,b   Fenyö, Eva Maria ^e   Spetz, Anna Lena ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Apoptosis; B cells; HIV 1; Immunization routes; T cells; Virus neutralization

Indexed keywords

ANTIGEN P24; APOPTOTIC HIV 1 MURINE LEUKEMIA VIRUS INFECTED CELL VACCINE; GLYCOPROTEIN GP 160; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEF PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VAGINA SECRETION; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; CYTOKINES; DRUG ADMINISTRATION ROUTES; FEMALE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LEUKEMIA VIRUS, MURINE; MICE; MICE, INBRED C57BL; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; NEUTRALIZATION TESTS; SPLEEN;

EID: 70350072669     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.016     Document Type: Article

References (42)

1. Larsson M., Beignon A.S., and Bhardwaj N. DC-virus interplay: a double edged sword. Semin Immunol 16 3 (2004) 147-161
2. Bevan M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143 5 (1976) 1283-1288
3. Yrlid U., and Wick M.J. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J Exp Med 191 4 (2000) 613-624
4. Schaible U.E., Winau F., Sieling P.A., Fischer K., Collins H.L., Hagens K., et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 9 8 (2003) 1039-1046
5. Cresswell P., Ackerman A.L., Giodini A., Peaper D.R., and Wearsch P.A. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 207 (2005) 145-157
6. Holmgren L., Szeles A., Rajnavolgyi E., Folkman J., Klein G., Ernberg I., et al. Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood 93 11 (1999) 3956-3963
7. Spetz A.L., Patterson B.K., Lore K., Andersson J., and Holmgren L. Functional gene transfer of HIV DNA by an HIV receptor-independent mechanism. J Immunol 163 2 (1999) 736-742
8. Bergsmedh A., Szeles A., Henriksson M., Bratt A., Folkman M.J., Spetz A.L., et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA 98 11 (2001) 6407-6411
9. Hoffmann T.K., Meidenbauer N., Dworacki G., Kanaya H., and Whiteside T.L. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 60 13 (2000) 3542-3549
10. Feng H., Zeng Y., Graner M.W., and Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 100 12 (2002) 4108-4115
11. Goldszmid R.S., Idoyaga J., Bravo A.I., Steinman R., Mordoh J., and Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 171 11 (2003) 5940-5947
12. Ignatius R., Marovich M., Mehlhop E., Villamide L., Mahnke K., Cox W.I., et al. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J Virol 74 23 (2000) 11329-11338
13. Ishii S., Hiroishi K., Eguchi J., and Mitamura K. Dendritic cell maturation induced by delivery of ultraviolet-mediated apoptotic colorectal cancer cell lines. Anticancer Res 23 3B (2003) 2457-2463
14. Johansson U., Walther-Jallow L., Smed-Sorensen A., and Spetz A.L. Triggering of dendritic cell responses after exposure to activated, but not resting, apoptotic PBMCs. J Immunol 179 3 (2007) 1711-1720
15. Steinman R.M., Turley S., Mellman I., and Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191 3 (2000) 411-416
16. Fadok V.A., Bratton D.L., and Henson P.M. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 108 7 (2001) 957-962
17. Ferguson T.A., Herndon J., Elzey B., Griffith T.S., Schoenberger S., and Green D.R. Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness. J Immunol 168 11 (2002) 5589-5595
18. Spetz A.L., Sorensen A.S., Walther-Jallow L., Wahren B., Andersson J., Holmgren L., et al. Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells. J Immunol 169 10 (2002) 5771-5779
19. Spector D.H., Wade E., Wright D.A., Koval V., Clark C., Jaquish D., et al. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol 64 5 (1990) 2298-2308
20. Andang M., Hinkula J., Hotchkiss G., Larsson S., Britton S., Wong-Staal F., et al. Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model. Proc Natl Acad Sci USA 96 22 (1999) 12749-12753
21. Belyakov I.M., and Berzofsky J.A. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20 3 (2004) 247-253
22. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5 10 (2005) 783-792
23. Hinkula J., Rollman E., Lundholm P., Benthin R., Okuda K., and Wahren B. Genetic immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo. Cells Tissues Organs 177 3 (2004) 169-184
24. Lyamuya E., Bredberg-Raden U., Albert J., Grankvist O., Msangi V., Kagoma C., et al. Comparison of in-house and commercial sample preparation and PCR amplification systems for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults. J Clin Microbiol 35 1 (1997) 278-280
25. VanCott T.C., Kaminski R.W., Mascola J.R., Kalyanaraman V.S., Wassef N.M., Alving C.R., et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 160 4 (1998) 2000-2012
26. Lundholm P., Asakura Y., Hinkula J., Lucht E., and Wahren B. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine 17 15-16 (1999) 2036-2042
27. Devito C., Zuber B., Schroder U., Benthin R., Okuda K., Broliden K., et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 173 11 (2004) 7078-7089
28. Kjerrstrom A., Hinkula J., Engstrom G., Ovod V., Krohn K., Benthin R., et al. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology 284 1 (2001) 46-61
29. Shi Y., Albert J., Francis G., Holmes H., and Fenyo E.M. A new cell line-based neutralization assay for primary HIV type 1 isolates. AIDS Res Hum Retroviruses 18 13 (2002) 957-967
30. Karlsson A., Parsmyr K., Sandstrom E., Fenyo E.M., and Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 32 2 (1994) 364-370
31. Bjorndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 71 10 (1997) 7478-7487
32. Morner A., Bjorndal A., Albert J., Kewalramani V.N., Littman D.R., Inoue R., et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 73 3 (1999) 2343-2349
33. Nordqvist A., and Fenyo E.M. Plaque-reduction assays for human and simian immunodeficiency virus neutralization. Methods Mol Biol 304 (2005) 273-285
34. Carotenuto P., Looij D., Keldermans L., de Wolf F., and Goudsmit J. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12 13 (1998) 1591-1600
35. Pantaleo G., Menzo S., Vaccarezza M., Graziosi C., Cohen O.J., Demarest J.F., et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 332 4 (1995) 209-216
36. Pilgrim A.K., Pantaleo G., Cohen O.J., Fink L.M., Zhou J.Y., Zhou J.T., et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 176 4 (1997) 924-932
37. Lauren A., Thorstensson R., and Fenyo E.M. Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): the kinetics of evolution to neutralization resistance are related to progression rate of disease. J Gen Virol 87 Pt 3 (2006) 595-606
38. Schnierle B.S., Stitz J., Bosch V., Nocken F., Merget-Millitzer H., Engelstadter M., et al. Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 94 16 (1997) 8640-8645
39. Hamilton J.A. GM-CSF in inflammation and autoimmunity. Trends Immunol 23 8 (2002) 403-408
40. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90 8 (1993) 3539-3543
41. Mach N., and Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 12 5 (2000) 571-575
42. Barouch D.H., Santra S., Tenner-Racz K., Racz P., Kuroda M.J., Schmitz J.E., et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 168 2 (2002) 562-568